How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

Disruption of Cholesterol Efflux by Coxib Medications and Inflammatory Processes

(2016) Allison B. Reiss et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Sind Biomarker ihr Geld wert?

(2011) Thomas Reinhold et al.   HERZ

Reducing QT liability and proarrhythmic risk in drug discovery and development

(2010) Jean-Pierre Valentin   BRITISH JOURNAL OF PHARMACOLOGY

Value of non-clinical cardiac repolarization assays in supporting the discovery and development of safer medicines

(2010) Jean-Pierre Valentin et al.   BRITISH JOURNAL OF PHARMACOLOGY

An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk

(2010) CE Pollard et al.   BRITISH JOURNAL OF PHARMACOLOGY

Emerging Anticancer Therapeutic Targets and the Cardiovascular System

(2010) Xuyang Peng et al.   CIRCULATION RESEARCH

Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics

(2010) Hui Cheng et al.   CIRCULATION RESEARCH

MiR423-5p As a Circulating Biomarker for Heart Failure

(2010) Anke J. Tijsen et al.   CIRCULATION RESEARCH

The Vulnerability of the Heart As a Pluricellular Paracrine Organ

(2010) Gilles W. De Keulenaer et al.   CIRCULATION RESEARCH

Recommendations for the use of cardiac troponin measurement in acute cardiac care

(2010) K. Thygesen et al.   EUROPEAN HEART JOURNAL

Cardiovascular system assessment best practices: a Safety Pharmacology Society meeting

(2010) Icilio Cavero   Expert Opinion On Drug Safety

Cancer Therapy-Associated Cardiotoxicity and Signaling in the Myocardium

(2010) Christian Zuppinger et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Importance of Blood Pressure Lowering in Type 2 Diabetes: Focus on ADVANCE

(2010) John Chalmers et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path Initiative

(2009) Jonathan P. Piccini et al.   AMERICAN HEART JOURNAL

Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives

(2009) Rashmi R Shah   BRITISH JOURNAL OF PHARMACOLOGY

Integrated risk assessment and predictive value to humans of non-clinical repolarization assays

(2009) Robert M Wallis   BRITISH JOURNAL OF PHARMACOLOGY

Report and Recommendations of the Workshop of the European Centre for the Validation of Alternative Methods for Drug-Induced Cardiotoxicity

(2009) Tina C. Stummann et al.   Cardiovascular Toxicology

The future of drug safety testing: expanding the view and narrowing the focus

(2009) James L. Stevens et al.   DRUG DISCOVERY TODAY

Physicochemical drug properties associated within vivotoxicological outcomes: a review

(2009) David A Price et al.   Expert Opinion on Drug Metabolism & Toxicology

Resting Heart Rate Pattern During Follow-Up and Mortality in Hypertensive Patients

(2009) Laura Paul et al.   HYPERTENSION

The Organic Cation Transporter, OCTN1, Expressed in the Human Heart, Potentiates Antagonism of the HERG Potassium Channel

(2009) Brian F McBride et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Lessons from 60 years of pharmaceutical innovation

(2009) Bernard Munos   NATURE REVIEWS DRUG DISCOVERY

A Sensitive Cardiac Troponin T Assay in Stable Coronary Artery Disease

(2009) Torbjørn Omland et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prediction of drug-related cardiac adverse effects in humans-B: Use of QSAR programs for early detection of drug-induced cardiac toxicities

(2009) Anna A. Frid et al.   REGULATORY TOXICOLOGY AND PHARMACOLOGY

A framework to assess the translation of safety pharmacology data to humans

(2009) Jean-Pierre Valentin et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies

(2009) B.D. Guth et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

Beyond the safety assessment of drug-mediated changes in the QT interval… what's next?

(2009) Michael K. Pugsley et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

A call for more integrated cardiovascular safety assessment

(2009) S.D. Pettit et al.   JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS

International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes

(2008) A S Bass et al.   BRITISH JOURNAL OF PHARMACOLOGY

Principles of Safety Pharmacology

(2008) M K Pugsley et al.   BRITISH JOURNAL OF PHARMACOLOGY

The failure of torcetrapib: what have we learned?

(2008) T R Joy et al.   BRITISH JOURNAL OF PHARMACOLOGY

Shape Signatures: New Descriptors for Predicting Cardiotoxicity In Silico

(2008) Dmitriy S. Chekmarev et al.   CHEMICAL RESEARCH IN TOXICOLOGY

Ligand Structural Aspects of hERG Channel Blockade

(2008) Alex Aronov   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Echocardiography, a non-invasive method for the assessment of cardiac function and morphology in preclinical drug toxicology and safety pharmacology

(2008) Gilles Hanton et al.   Expert Opinion on Drug Metabolism & Toxicology

Early clinical development: Evaluation of drug-induced torsades de pointes risk

(2008) Torbjorn Vik et al.   PHARMACOLOGY & THERAPEUTICS